Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups (Q36642224)
Jump to navigation
Jump to search
scientific article published on August 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups |
scientific article published on August 2000 |
Statements
1 reference
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups (English)
1 reference
G Freyer
1 reference
P Rougier
1 reference
R Bugat
1 reference
J P Droz
1 reference
M Marty
1 reference
H Bleiberg
1 reference
D Mignard
1 reference
L Awad
1 reference
P Herait
1 reference
S Culine
1 reference
V Trillet-Lenoir
1 reference
1 August 2000
1 reference
1 reference
431-437
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference